Clinical trialPhase 2Completed
Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
Initial Evaluation of Role of Early Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 11 December 2017
- Ended
- 15 June 2021
- Enrollment
- 6 participants
- Sites
- 1
- Primary outcomes
- Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy; Change From Baseline in SUV Peak of Lesion After 2 Cycles of Chemotherapy; Change From Baseline in Proliferative Tumor Volume After 2 Cycles Chemotherapy; 1 Year Overall Survival; 2 Year Overall Survival
- Sponsor type
- Academic / other
- Results posted
- 8 November 2022
- Last update
- 8 November 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 8 November 2022
- Primary outcome
- Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of ChemotherapyDiagnostic (Interim FLT PET/CT): 27.45 (-35.8 to 90.96), n = 2Values: mean percentage of SUV Max change, Full RangeTime frame: Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)No analysis posted for this outcome (outcome 1)
- OS
- 1 Year Overall SurvivalDiagnostic (Interim FLT PET/CT): 67, n = 6Values: percentage of subjectsTime frame: Baseline(pre-treatment), until date of first observed death, assessed up to 1 yearNo analysis posted for this outcome (outcome 4)
- OS
- 2 Year Overall SurvivalDiagnostic (Interim FLT PET/CT): 33, n = 6Values: percentage of subjectsTime frame: Baseline(pre-treatment), until date of first observed death, assessed up to 2 yearsNo analysis posted for this outcome (outcome 5)
- Primary outcome, no data
- Change From Baseline in SUV Peak of Lesion After 2 Cycles of ChemotherapyThe registry’s note: Data was not collected.
- Primary outcome, no data
- Change From Baseline in Proliferative Tumor Volume After 2 Cycles ChemotherapyThe registry’s note: Data was not collected
- Participants
- Diagnostic (Interim FLT PET/CT): 6 started, 2 completed
- Serious adverse events
- Diagnostic (Interim FLT PET/CT): 0 of 6Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
- PFS · 6 Months Progression Free Survival
- Diagnostic (Interim FLT PET/CT) 40, n=5 [percentage of subjects]
- PFS · 1 Year Progression Free Survival
- Diagnostic (Interim FLT PET/CT) 40, n=5 [percentage of subjects]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To assess if percentage change in 18F-FLT PET/CT quantitative parameters (SUV max, or SUV peak or proliferative tumor volume) after 2 cycles of neoadjuvant chemotherapy can predict overall survival at 1 and 2 years and progression free survival at 6 months and 1 year in patients with borderline resectable or locally advanced, pancreatic adenocarcinoma.
Detailed description public domain (ClinicalTrials.gov)
The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up. Visit 1: Patients will have at least one visit with investigator (or investigator designee) prior to the study to review clinical history and prior treatment of pancreatic adenocarcinoma, and to explain the study. Correlative radiology studies including CT, MRI and 18F FDG-PET/CT as per institutional routine clinical care, and any clinically-directed laboratory tests performed as part of staging must be performed within 30 days of the 18F FLT-PET/CT Visit 2 (Optional): The 18F-FDG-PET/CT may be done as a research scan, if the patient is unable to obtain a clinically-directed 18F-FDG-PET/CT as part of their clinical care or within 30 days of 18F FLT-PET/CT. The research 18F-FDG-PET/CT, in this instance, will be identical in procedure to the institution's clinical 18F-FDG-PET/CT. The blood glucose level will be \< 200 mg/dl, before 18F-FDG injection, which is institutional standard clinical protocol. The following additional patient data will be obtained: histological diagnosis of primary and/or metastatic disease, date of diagnosis of primary and metastatic disease, gender, height, weight (for BMI), ECOG score and confirmation of absence of prior treatment. Visit 3: Day of 18F-FLT-PET/CT: The patient will have an intravenous line placed in the hand or arm, 18F-FLT-PET/CT will be given by 1-2 minute IV push, and the dose administered will be approximately 5 mCi (+/- 20% dose). After approximately 60 +/- 10 minutes of uptake time, the patient will be positioned supine in the PET/CT scanner for standard whole body PET/CT scan from the skull base to mid-thigh. This scan will take approximately 20-30 min. The window from FLT PET/CT baseline study to initiation of chemotherapy should be no more than 30 days. Visit 4: Day of Interim 18F-FLT-PET/CT: The interim 18F FLT-PET/CT will be performed after the 2nd cycle of chemotherapy regimen, but before the commencement of 3rd cycle. The second 18F-FLT-PET/CT study must be performed on the same scanner as the first 18F FLT-PET/CT and the imaging protocol described in Visit 3 should be closely followed. Study duration: Clinical Follow Up: Standard of care clinical follow-up data will be collected up to 2 years following the end of chemotherapy. .
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Change From Baseline in Summed Standardized Uptake Value (SUVmax) of Lesion After 2 Cycles of Chemotherapy [Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)]. Mean, percentage of SUV Max change (Full Range). Diagnostic (Interim FLT PET/CT) (n=2): 27.45 (-35.8 to 90.96).
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Change From Baseline in SUV Peak of Lesion After 2 Cycles of Chemotherapy [Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)].
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Change From Baseline in Proliferative Tumor Volume After 2 Cycles Chemotherapy [Baseline(pre-treatment), 2 cycles after starting chemotherapy (each cycle 14 days)].
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
1 Year Overall Survival [Baseline(pre-treatment), until date of first observed death, assessed up to 1 year]. Number, percentage of subjects. Diagnostic (Interim FLT PET/CT) (n=6): 67.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
2 Year Overall Survival [Baseline(pre-treatment), until date of first observed death, assessed up to 2 years]. Number, percentage of subjects. Diagnostic (Interim FLT PET/CT) (n=6): 33.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
6 Months Progression Free Survival [Baseline (pre-treatment), until date of first observed progression, assessed up to 6 months]. Number, percentage of subjects. Diagnostic (Interim FLT PET/CT) (n=5): 40.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
1 Year Progression Free Survival [Baseline(pre-treatment), until date of first observed progression, assessed up to 1 year]. Number, percentage of subjects. Diagnostic (Interim FLT PET/CT) (n=5): 40.